Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Update

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 192,015 shares, a growth of 81.0% from the December 31st total of 106,098 shares. Based on an average daily volume of 194,094 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.4% of the company’s shares are sold short. Approximately 1.4% of the company’s shares are sold short. Based on an average daily volume of 194,094 shares, the days-to-cover ratio is currently 1.0 days.

Hedge Funds Weigh In On Kairos Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Kairos Pharma during the second quarter worth approximately $44,000. Two Sigma Investments LP purchased a new stake in shares of Kairos Pharma during the 3rd quarter valued at about $54,000. Finally, FNY Investment Advisers LLC purchased a new position in Kairos Pharma during the third quarter valued at $27,000.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kairos Pharma has a consensus rating of “Buy” and an average price target of $8.33.

Kairos Pharma Stock Down 0.1%

NYSEAMERICAN:KAPA traded down $0.00 during mid-day trading on Friday, reaching $0.66. 126,041 shares of the stock were exchanged, compared to its average volume of 184,002. The stock has a market capitalization of $13.83 million, a P/E ratio of -2.14 and a beta of 2.28. The company has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $1.02. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.